Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma-Reference-Cited by-同舟云学术

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma

Published:2019-08-09 Issue:3 Volume:144 Page:563-572
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Miller Todd W.,Traphagen Nicole A.,Li Jing,Lewis Lionel D.,Lopes Beatriz,Asthagiri Ashok,Loomba Johanna,De Jong Jenny,Schiff David,Patel Sohil H.,Purow Benjamin W.,Fadul Camilo E.^ORCID

Funder

Novartis Pharmaceuticals

Norris Cotton Cancer Center

Radiologic Society of North America

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-019-03258-0.pdf

Reference41 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

3. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. https://doi.org/10.1056/NEJMra0708126

4. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF (2014) Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife 3. https://doi.org/10.7554/eLife.02872

5. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331–342

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFLAM exhibits oncogenic activity and shows promise as a prognostic biomarker and therapeutic target in glioblastoma;International Immunopharmacology;2024-09

2. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma;Holistic Integrative Oncology;2024-05-28

3. Synthesis and Preclinical Evaluation of Novel ⁶⁸Ga-DOTA-RBB as Potential PET Radiotracer for Imaging CDK4/6 in Tumors;ACS Medicinal Chemistry Letters;2024-05-14

4. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas;Science Translational Medicine;2023-09-06

5. Preparation and Evaluation of [¹⁸F]AlF-NOTA-PBB for PET Imaging of Cyclin-dependent Kinase 4/6 in Tumors;Molecular Pharmaceutics;2023-08-24